Overview
Dr. Leiman is an Associate Professor of Medicine and gastroenterologist specializing in esophageal diseases and swallowing disorders, such as eosinophilic esophagitis (EoE), motility disorders such as achalasia, and gastroesophageal reflux disease (GERD) as well as its associated complications including Barrett’s esophagus (BE). His busy clinical practice dovetails with his academic focus on health services research, including patient outcomes and clinical quality measurement. He is also a PI for several ongoing multicenter clinical trials investigating novel therapies for EoE and GERD.
Dr. Leiman has mentored numerous medical students, residents, and GI fellows on research and quality improvement projects resulting in research awards, presentations at national meetings, and peer-reviewed publications.
Current Appointments & Affiliations
Recent Publications
AGA Institute Quality Indicator Development for Irritable Bowel Syndrome.
Journal Article Gastroenterology · March 2025 Full text Link to item CiteIdentification of gaps in the delivery of high-quality care of patients with eosinophilic esophagitis.
Journal Article Dis Esophagus · January 7, 2025 Quality indicators (QIs) are standardized metrics that can be used to quantify health care delivery and identify important areas for practice improvement. Nine QIs pertaining to the diagnosis and management of eosinophilic esophagitis (EoE) were recently e ... Full text Link to item CitePreoperative dysphagia and adverse postoperative outcomes in middle aged and older adults.
Journal Article J Clin Anesth · January 2025 BACKGROUND: Dysphagia is a swallowing impairment with adverse health consequences. The impact of preoperative dysphagia on postoperative outcomes is not known. This study will examine the association between preoperative dysphagia and postoperative outcome ... Full text Link to item CiteRecent Grants
TARGET-GASTRO - GI-02 Pro00114153 Longitudinal, observational, non-interventional study of FDA-approved medications and other therapies used in usual clinical practice.
Clinical TrialPrincipal Investigator · Awarded by TARGET PharmaSolutions, Inc. · 2024 - 2038A PHASE 1, OPEN-LABEL, SINGLE-SEQUENCE STUDY TO EVALUATE POTENTIAL DISEASE-MEDIATED DRUG-DRUG INTERACTION WITH SELECTED CYTOCHROME P450 SUBSTRATES IN ADULT SUBJECTS WITH ACTIVE OSINOPHILIC ESOPHAGITIS RECEIVING CENDAKIMAB
Clinical TrialPrincipal Investigator · Awarded by Celgene International II Sarl · 2023 - 2027A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis. Celldex_CDX0159-08_Pro00112764
Clinical TrialPrincipal Investigator · Awarded by Celldex Therapeutics, Inc. · 2023 - 2026View All Grants